Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70223 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Kevin T Pritchard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massach…. Hauptthemen laut MEDLINE: Analgesics, Opioid, Liver Cirrhosis, Medicare, Chronic Pain. Die Arbeit nennt 43 Literaturangaben.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Older adults with cirrhosis commonly experience chronic noncancer pain managed with chronic opioid therapy. Current guidelines recommend opioid deprescribing for high‐risk populations, including in cirrhosis, but data on tapering and discontinuation are scarce. We described opioid discontinuation rates and identified predictors of tapering or discontinuation. This retrospective cohort study of Medicare fee‐for‐service beneficiaries ( N = 800,763) ≥ 65 years with continuous opioid use for ≥ 90 days. The primary outcome was opioid discontinuation (i.e., a gap in refills > 30 days). The secondary outcome included opioid tapering (i.e., a 35% decrease in average daily morphine milligram equivalents; [yes/no]). The primary exposure was diagnosed cirrhosis severity (i.e., none, compensated, decompensated). We estimated discontinuation rates using the Kaplan–Meier method, time to opioid discontinuation using proportional hazards regression, and predictors of tapering with logistic regression. After 1 year, 37% (95% CI = 37–37%) of individuals without cirrhosis discontinued opioids, similar to those with compensated (36% (34–37%)) and decompensated (37% (35–39%)) cirrhosis. Age did not modify the adjusted association between cirrhosis status and discontinuation (Wald χ 2 (4) = 7.72, p = 0.10) but calendar year (pre/post COVID‐19) did (Wald χ 2 (1) = 26.57, p < 0.001). This finding indicated higher deprescribing rates prior to the pandemic, especially for those without cirrhosis (HR, 1.32; 95% CI, 1.31–1.33) compared with those with cirrhosis (HR, 1.13; 95% CI, 1.06–1.20). Non‐opioid analgesic use, fall history, and frailty significantly increased the odds of tapering. In conclusion, these findings may reflect a lack of safe analgesic alternatives or higher pain burden in cirrhosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Kevin T Pritchard, Qiaoxi Chen, Kueiyu Joshua Lin, Tracey Simon
Zitieren
APA
Pritchard, K. T., Chen, Q., Lin, K. J., & Simon, T. (2026). Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70223
Vancouver
Pritchard KT, Chen Q, Lin KJ, Simon T. Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70223
BibTeX
@article{Pritchard2026,
author = {Pritchard, Kevin T and Chen, Qiaoxi and Lin, Kueiyu Joshua and Simon, Tracey},
title = {Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70223}
}
EUVIMED